Centessa Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.11.24	Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update (GlobeNewswire)
13.09.24	Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares (GlobeNewswire)
11.09.24	Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares (GlobeNewswire)
10.09.24	Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers (Benzinga)
10.09.24	Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers (GlobeNewswire)
27.08.24	Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research (GlobeNewswire)
13.08.24	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 (GlobeNewswire)
13.05.24	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 (GlobeNewswire)
24.04.24	Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares (GlobeNewswire)
23.04.24	Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares (GlobeNewswire)
22.04.24	Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 (GlobeNewswire)
28.03.24	Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 (GlobeNewswire)
10.12.23	Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia (GlobeNewswire)
13.11.23	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 (GlobeNewswire)
25.10.23	Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders (GlobeNewswire)
14.08.23	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023 (GlobeNewswire)
10.07.23	Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors (GlobeNewswire)
24.05.23	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
22.05.23	Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B (GlobeNewswire)
12.05.23	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 (GlobeNewswire)
30.03.23	Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022 (GlobeNewswire)
27.03.23	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
01.03.23	Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines (GlobeNewswire)
10.11.22	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022 (GlobeNewswire)
03.11.22	Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting (GlobeNewswire)
31.10.22	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
20.09.22	Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2 (GlobeNewswire)
14.09.22	Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B (GlobeNewswire)
12.09.22	Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index (GlobeNewswire)
29.08.22	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
10.08.22	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874 (GlobeNewswire)
25.07.22	Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs (GlobeNewswire)
01.07.22	Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors (GlobeNewswire)
06.06.22	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
05.06.22	Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting (GlobeNewswire)
02.06.22	Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) (GlobeNewswire)
16.05.22	Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
30.03.22	Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update (GlobeNewswire)
23.03.22	Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day (GlobeNewswire)
07.03.22	Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise (GlobeNewswire)
24.02.22	Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease (GlobeNewswire)
14.12.21	Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notic (GlobeNewswire)
13.12.21	Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index (GlobeNewswire)
15.11.21	Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
10.11.21	Centessa Pharmaceuticals to Present at Upcoming Conferences in 2021 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Centessa Pharmaceuticals PLC (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten